Charles Schwab Investment Management Inc. Decreases Holdings in United Therapeutics Corporation $UTHR

Charles Schwab Investment Management Inc. reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 335,885 shares of the biotechnology company’s stock after selling 14,973 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.74% of United Therapeutics worth $96,517,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in UTHR. AE Wealth Management LLC acquired a new position in United Therapeutics in the first quarter valued at approximately $248,000. Avantax Advisory Services Inc. raised its holdings in United Therapeutics by 226.5% during the first quarter. Avantax Advisory Services Inc. now owns 1,933 shares of the biotechnology company’s stock worth $596,000 after purchasing an additional 1,341 shares in the last quarter. HB Wealth Management LLC lifted its position in shares of United Therapeutics by 12.6% during the 1st quarter. HB Wealth Management LLC now owns 1,200 shares of the biotechnology company’s stock worth $370,000 after buying an additional 134 shares during the last quarter. LPL Financial LLC boosted its holdings in shares of United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of United Therapeutics in the 1st quarter valued at $958,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $400.56, for a total transaction of $9,012,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 578,435 shares of company stock valued at $252,731,147. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 0.5%

Shares of UTHR stock opened at $485.97 on Friday. The stock’s 50-day moving average price is $447.65 and its 200 day moving average price is $361.75. The stock has a market capitalization of $20.92 billion, a PE ratio of 18.41, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $492.62.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the business posted $6.39 EPS. Analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on UTHR. Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Cantor Fitzgerald raised their price target on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Tuesday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.